Form 4: Biogen Director Maria Freire Increases Stake with Share Acquisition

Biogen Inc. Director Maria C. Freire has acquired 2,370 shares of common stock, increasing her beneficial ownership to 6,815 shares.

Summary

• Maria C. Freire, a Director of Biogen Inc. (BIIB), reported a change in her beneficial ownership of the company's common stock.
• On June 17, 2025, Dr. Freire acquired 2,370 shares of Biogen common stock.
• The acquisition price for these shares was $0, indicating that the shares were likely granted as part of an equity compensation plan rather than purchased.
• Following this transaction, Dr. Freire's total beneficial ownership of Biogen common stock stands at 6,815 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director increasing their stake, even through a grant, generally indicates confidence in the company. However, it's a routine transaction and not indicative of significant new information.

Positives

• The acquisition of additional shares by a director, even if granted, generally signals continued alignment of management's interests with those of shareholders.
• An increase in beneficial ownership by a director can be viewed as a positive indicator of confidence in the company's future prospects.

Future Outlook

This SEC Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine disclosure of an insider transaction and does not provide information related to broader industry trends or competitive landscape. It reflects an individual director's equity holdings.

Related Party Transactions

• Maria C. Freire, a Director of Biogen Inc., acquired 2,370 shares of common stock from the company at a price of $0, which is a standard related-party transaction for equity compensation.

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests more closely with those of the shareholders, potentially fostering greater confidence in management's commitment to long-term value creation.

Key Dates

Keywords

Biogen, BIIB, SEC Form 4, Insider Transaction, Director, Stock Acquisition, Beneficial Ownership, Equity Compensation